Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FTX002600 + FTX003059
- Development stage
- Preclinical
- Lead developer
- Fountain Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
FTX002600 + FTX003059 is a topical small molecule combination therapy under development by Fountain Therapeutics (also referred to as Green Fountain). The program is currently in the IND-enabling stage, targeting various forms of skin atrophy, including age-associated, glucocorticoid-induced, and weight loss-induced skin atrophy (colloquially known as "Wegovy Face"). Additionally, the combination is being explored for the treatment of scleroderma and as a medical aesthetic alternative to traditional dermal fillers or neurotoxins. The therapy aims to address the underlying biological drivers of skin thinning and loss of elasticity.
Beyond the preview
Go deeper on FTX002600 + FTX003059.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FTX002600 + FTX003059.